Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:26:59 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - http://www.atossagenetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q0.11.38·1.551.51.53+0.010.7900.01,2702,3011.58  1.595  1.512.31  0.590119:17:35Apr 1515 min RT 2¢

Recent Trades - Last 10 of 2301
Time ETExPriceChangeVolume
19:17:35Q1.50-0.0246
19:14:50Q1.5019-0.0181265
18:58:43Q1.550.0317
18:58:16Q1.550.03125
18:44:00Q1.540.02100
18:40:17Q1.540.02100
18:39:58Q1.540.02500
18:23:57Q1.550.032
17:42:29Q1.50-0.02100
17:22:57Q1.52 2

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-15 08:30U:ATOSNews ReleaseAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO(TM)) in Women with ER+/HER2- Breast Cancer
2024-04-11 08:30U:ATOSNews ReleaseAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
2024-04-09 11:59U:ATOSNews ReleaseAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
2024-04-01 16:00U:ATOSNews ReleaseAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
2024-03-19 08:30U:ATOSNews ReleaseAtossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
2024-03-18 08:30U:ATOSNews ReleaseAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
2024-03-12 08:30U:ATOSNews ReleaseAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
2024-03-06 08:30U:ATOSNews ReleaseData from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
2024-02-22 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
2024-02-07 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Full Enrollment of ‚  (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
2024-01-09 08:30U:ATOSNews ReleaseAtossa Therapeutics Issues Letter to Shareholders
2023-12-04 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
2023-11-20 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
2023-11-13 09:00U:ATOSNews ReleaseAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-09 09:00U:ATOSNews ReleaseAtossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
2023-10-30 13:00U:ATOSNews ReleaseQuantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
2023-10-11 08:30U:ATOSNews ReleaseFast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
2023-09-18 11:14U:ATOSNews ReleaseApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
2023-09-18 08:30U:ATOSNews ReleaseAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023